^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

TP53 mutation influences the efficacy of treatment of colorectal cancer cell lines with a combination of sirtuin inhibitors and chemotherapeutic agents

Published date:
05/29/2020
Excerpt:
The HCT116 (KRASmut and TP53wt) and SW620 (KRASmut and TP53mut) cells were treated with NAM (a broad spectrum SIRT inhibitor), EX527 (a SIRT1 inhibitor) or AGK2 (a SIRT2 inhibitor) and the respective IC50 values were calculated (Fig. 1). Similarly, the IC50 values of cisplatin, 5-FU, irinotecan, oxaliplatin, paclitaxel, EGFR inhibitor gefitinib, PI3K inhibitor LY294002, pyruvate dehydrogenase kinase inhibitor DCA and the gluconeogenesis inhibitor metformin were determined (Fig. 2). These findings suggested that, SIRT inhibitors and chemotherapeutic agents had tumor inhibitory effects on CRCs.
DOI:
10.3892/etm.2020.8818